ArticleCell2024
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.
Erratum issued Registry-linked trialAbstract read
In one paragraph
Article in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03934541 (A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants), which is not on this map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants
Who cites it
42 citing papers in PubMed.
- Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial.Science translational medicine · 2025Trial
- Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAb induction in SHIV-infected rhesus macaques.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.medRxiv : the preprint server for health sciences · 2026Article
- Article
- What's Hot in HIV in 2025-A Basic and Translational Science Review From IDWeek 2025.The Journal of infectious diseases · 2026Review
- Clonal dynamics of germinal center refueling by secondary immunization.bioRxiv : the preprint server for biology · 2026Article
- Charting the Path Forward for HIV Immune-Based Prevention: Contributions of the Division of AIDS at NIAID.Vaccines · 2026Article
- A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults.medRxiv : the preprint server for health sciences · 2026Article
- Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response.Journal of virology · 2026Review
- Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses.EBioMedicine · 2026Article
- Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300).medRxiv : the preprint server for health sciences · 2026Article
- Decoding the glycan shield: Immune recognition and response to the HIV-1 envelope trimer.The Journal of biological chemistry · 2026Review
- Vaccine elicitation of HIV-1 neutralizing antibodies against both V2 apex and fusion peptide in rhesus macaques.Cell reports · 2026Article
- Virus glycoprotein nanodisc platform for vaccine analytics.Nature communications · 2026Article
- Heterologous immunization modulates B-cell epitope competition between helper peptides and the MPER segment in MPER/liposome vaccines.NPJ vaccines · 2026Article
- Functional Convergence of Genetically Diverse B-Cell Receptors in Simian-HIV Infected Rhesus Macaques.bioRxiv : the preprint server for biology · 2026Article
- Innovative Single-Cell Sequencing Techniques for B cell Analysis and Their Implications for Rational HIV-1 Vaccine Design.Current HIV research · 2026Review
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- Accelerating Innovation: Advancing Opportunities in HIV Vaccine Development.Current HIV research · 2026Review
- Integration of Preclinical and Clinical Vaccine Safety and Immunogenicity Testing for Development of a Pediatric HIV Vaccine to Achieve Protective HIV Immunity Prior to Adolescence.Current HIV research · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
48 authors.
Wilton B WilliamsDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunobiology, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: wilton.williams@duke.edu.
S Munir AlamDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: munir.alam@duke.edu.
Gilad OfekDepartment of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA.
Nathaniel ErdmannUniversity of Alabama Medical Center, Birmingham, AL 35223, USA.
David C MontefioriDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA.
Michael S SeamanBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Kshitij WaghLos Alamos National Laboratory, Los Alamos, NM 87545, USA; New Mexico Consortium, Los Alamos, NM 87544, USA.
Bette KorberLos Alamos National Laboratory, Los Alamos, NM 87545, USA; New Mexico Consortium, Los Alamos, NM 87544, USA.
Robert J EdwardsDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
Katayoun MansouriDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Amanda EatonDepartment of Surgery, Duke School of Medicine, Durham, NC 27710, USA.
Derek W CainDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
Mitchell MartinDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
JongIn HwangDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Aria Arus-AltuzDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Xiaozhi LuDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Fangping CaiDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
Nolan JamiesonDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
Robert ParksDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Maggie BarrDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Andrew FoulgerDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Kara AnastiDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Parth PatelDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Salam SammourDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Ruth J ParsonsDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Xiao HuangDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Jared LindenbergerDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Susan FeticsDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Katarzyna JanowskaDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Aurelie NiyongaboDepartment of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA.
Benjamin M JanusDepartment of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA.
Anagh AstavansDepartment of Cell Biology and Molecular Genetics, University of Maryland, College Park, MD 20742, USA.
Christopher B FoxAccess to Advanced Health Institute, Seattle, WA 98102, USA.
Ipsita MohantyDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Tyler EvangelousDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Yue ChenDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Madison BerryDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Helene KirshnerDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Elizabeth Van ItallieDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunobiology, Duke School of Medicine, Durham, NC 27710, USA; Department of Molecular Genetics and Microbiology, Duke School of Medicine, Durham, NC 27710, USA.
Kevin WieheDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA.
Kristen W CohenFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
M Juliana McElrathFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Lawrence CoreyFred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Priyamvada AcharyaDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke School of Medicine, Durham, NC 27710, USA; Department of Biochemistry, Duke School of Medicine, Durham, NC 27710, USA.
Stephen R WalshBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: swalsh@bwh.harvard.edu.
Lindsey R BadenBrigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: lbaden@bwh.harvard.edu.
Barton F HaynesDuke Human Vaccine Institute, Duke School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke School of Medicine, Durham, NC 27710, USA; Department of Integrative Immunobiology, Duke School of Medicine, Durham, NC 27710, USA; Duke Global Health Institute, Duke School of Medicine, Durham, NC 27710, USA. Electronic address: barton.haynes@duke.edu.
Funding
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI SANTRA, SAMPA · 2012 to 2018
$204.7MNonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodiesUM1AI144371 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2019 to 2025
$190.4MProject 3 - Dynamics of latent HIV-1 reservoirs: High resolution antigenic mapping and strategies to block reboundU54AI170752 · NIAID · DUKE UNIVERSITY · PI Priyamvada Acharya · 2022 to 2026
$32.0MOptimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogensR37AI150590 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Beatrice H Hahn · 2019 to 2026
$6.9MGates Foundation INV-007688NIAID NIH HHS R37 AI150590NIAID NIH HHS U54 AI170752NIAID NIH HHS UM1 AI100645NIAID NIH HHS UM1 AI144371
Abstract
A critical roadblock to HIV vaccine development is the inability to induce B cell lineages of broadly neutralizing antibodies (bnAbs) in humans. In people living with HIV-1, bnAbs take years to develop. The HVTN 133 clinical trial studied a peptide/liposome immunogen targeting B cell lineages of HIV-1 envelope (Env) membrane-proximal external region (MPER) bnAbs (NCT03934541). Here, we report MPER peptide-liposome induction of polyclonal HIV-1 B cell lineages of mature bnAbs and their precursors, the most potent of which neutralized 15% of global tier 2 HIV-1 strains and 35% of clade B strains with lineage initiation after the second immunization. Neutralization was enhanced by vaccine selection of improbable mutations that increased antibody binding to gp41 and lipids. This study demonstrates proof of concept for rapid vaccine induction of human B cell lineages with heterologous neutralizing activity and selection of antibody improbable mutations and outlines a path for successful HIV-1 vaccine development.
Indexed as
AIDS VaccinesAntibodies, NeutralizingB-LymphocytesHIV-1HIV AntibodiesCell Lineageenv Gene Products, Human Immunodeficiency VirusHIV Envelope Protein gp41HIV InfectionsHumansLiposomesMutationAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesHIV Envelope Protein gp41Liposomes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03934541ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.